KINGSTON, N.J., March 12, 2012 /PRNewswire-USNewswire/ -- Martin Tuchman, Chairman of the Parkinson's Unity Walk and The Parkinson Alliance, announced today that funds raised through the Parkinson's community helped support the research that led to this breakthrough.
Investigators at David Geffen School of Medicine at UCLA have reported the ability of a novel molecule CLRO1 (called a "molecular tweezer") to inhibit toxicity due to abnormal aggregation of a protein synuclein. Synuclein is widely believed to cause neuron death in human Parkinson's disease due to its tendency to form abnormal aggregations within neurons. The investigators found that CLRO1 both prevented and broke up a-synuclein aggregates.
The research, "A Novel 'Molecular Tweezer' Inhibitor of a-Synuclein Neurotoxicity in Vitro and in Vivo" appears in the current online edition (2012 February 29) of the journal Neurotherapeutics.
A great deal of the money raised by the Parkinson's organizations goes to fund ground breaking research; a level of pride is felt by the community that these dollars helped to fund this extraordinary and most promising research.
Dr. Robert E. Burke, Professor of Neurology and Pathology at Columbia University Medical Center and member of the Board of Directors of the Parkinson's Unity Walk, who did not participate in the research, stated: "This is a highly novel and promising approach aimed directly at a principal culprit in human Parkinson's disease, the protein synuclein."
About The Parkinson Alliance
The Parkinson Alliance is a Kingston, NJ-based national non-profit organization dedicated to raising funds to help finance the most promising research to find the cause and cure for Parkinson's disease. It is the umbrella organization for Team Parkinson, and its signature event, the annual Parkinson's Unity Walk, to take place on Saturday, April 28 in New York's Central Park. For more information, visit www.parkinsonalliance.org.
Chief Executive Officer
The Parkinson Alliance
SOURCE Parkinson Alliance